Navigation Links
Keryx Biopharmaceuticals' Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Date:9/14/2009

e kidney, the five-year survival rate is 60 to 70 percent; but the survival rate is considerably lower after the cancer has metastasized to other parts of the body. Even with the recent approval of several biological therapies for the treatment of advanced metastatic RCC (VEGF inhibitors, sunitinib and sorafenib, and mTOR inhibitors everolimus and temsirolimus), the National Cancer Institute reports a rising incidence of RCC with incidence and mortality rates more than twice as high in men as in women. In 2009, an estimated 49,000 new cases of RCC and 11,000 deaths attributable to RCC are expected in the US.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in pa
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014  Semler Scientific, Inc. (Nasdaq: ... company that develops patented products that assist healthcare ... today reported financial results for the third quarter ... "In the third quarter of 2014, ... M.D., chief executive officer of Semler.  "We moved ...
(Date:10/31/2014)... 31, 2014  Zebra Imaging, Inc., the world,s ... today a strategic partnership with the Zygote Media ... anatomy and biomedical models for animation and visual ... markets.  Zygote maintains the world,s most comprehensive library ... has pioneered development of high-end solid 3D anatomy ...
(Date:10/31/2014)... SAN FRANCISCO , Oct. 31, 2014 /PRNewswire/ ... innovative therapeutics, today announced a $26.5 million Series ... global investment firm founded by a team of ... sciences.  Other investors participating in the round include ... Venture Fund.  Representatives from Clarus Ventures and Frazier ...
Breaking Medicine Technology:Semler Reports Third Quarter 2014 Financial Results 2Semler Reports Third Quarter 2014 Financial Results 3Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures 2
... Oct. 6, 2010 Arena Pharmaceuticals, Inc. (Nasdaq: ... lorcaserin presentations at Obesity 2010, the 28th Annual Scientific ... Lorcaserin, which Arena discovered and developed, is intended for ... loss, in patients who are obese (Body Mass Index, ...
... N.J., and SAN ANTONIO, Oct. 6 ... company, and Mission Pharmacal Company, a privately-held ... market announced today their exclusive co-promotion agreement ... to obstetrician,s, gynecologists and other women,s health ...
Cached Medicine Technology:Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010 2Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010 3Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010 4Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 2Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 3Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 4
(Date:10/31/2014)... Nearly one out of four older Americans say that ... or unwanted medical treatment, according to the latest issue ... & Aging Report ( PP&AR ), which goes ... accountable when they fail to honor patients, end-of-life health ... Advanced Illness Care: Issues and Options ," features 12 ...
(Date:10/31/2014)... Denver, Colorado (PRWEB) October 31, 2014 ... reveals that this workout program was developed by Dan ... also become well-known as a fitness professional and life ... stubborn fat and having toned muscles is not impossible ... in based on suspension training. Suspension training promises efficiency ...
(Date:10/31/2014)... drug combination that can trigger the self-destruct process in ... treatments, according to research that will be presented at ... Liverpool next week*. , When healthy cells are no ... in self destruction. But cancer cells swerve away from ... cells grow out of control – causing tumours to ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 In an effort ... patients, Dr. Majid Jamali announced he will soon offer orthodontics ... by the end of November. , To build upon ... Surgery of New York has become known for, Dr. Jamali ... degrees from such top learning institutions as UCLA, Stanford and ...
(Date:10/31/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its new report, ... indoor air quality (IAQ) market is expected to grow to ... (CAGR) of 7% over the next five years. The equipment ... 7.4%. , Since 2012, continuing media attention focused on ... diseases such as bird flu and the increase in chronic ...
Breaking Medicine News(10 mins):Health News:Advance directives can benefit patients, families, and health care system 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 3Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3
... Encouraging Families to Be Incredibly Active and Healthy, American Egg ... 13 Today, the nation,s egg farmers will delight thousands ... eggs for the 2009 White House Easter Egg Roll. ... together families to hunt for and race Easter Eggs on ...
... used tiny molecules called microRNAs to help turn adult mouse cells back to ... stem cells , they have the capacity to become any cell type in ... ... researchers has for the first time used tiny molecules called microRNAs to help ...
... lung cancer are less likely to receive recommended chemotherapy and ... no signs of lessening. That is the conclusion of a ... CANCER , a peer-reviewed journal of the American Cancer ... provide appropriate treatments for black patients and to educate them ...
... notion that females only receive finite number of eggs ... Researchers in China have demonstrated that female ovaries may ... subsequently producing offspring. , That runs counter to the ... with a finite number of the eggs or oocytes ...
... ValueRays® ergonomic computer accessories provide infrared heat therapy using infrared ... your hand pain diagnosis results in cold computer hands and ... your computer provides warmth and relief. , ... ...
... Discovery advances search for better treatments, experts say, , , ... they,ve spotted a gene variant that may raise the ... may lead to new drug treatments. , The study ... had multiple members with schizophrenia. A functional DNA change ...
Cached Medicine News:Health News:America's Egg Farmers to Participate in Annual White House Easter Egg Roll Today 2Health News:America's Egg Farmers to Participate in Annual White House Easter Egg Roll Today 3Health News:UCSF Team Closer to Creating Safe Embryonic-Like Stem Cells 2Health News:UCSF Team Closer to Creating Safe Embryonic-Like Stem Cells 3Health News:UCSF Team Closer to Creating Safe Embryonic-Like Stem Cells 4Health News:Racial disparities persist in the treatment of lung cancer 2Health News:Stem Cells Spur New Eggs in Ovaries of Adult Mice 2Health News:Stem Cells Spur New Eggs in Ovaries of Adult Mice 3Health News:Arthritis Hand Pain Relief: Infrared Heat Therapy Ergonomic Computer Workstation 2Health News:Gene Variant Tied to Schizophrenia 2
The Skirts and Vests are made with .50mm Pb in the front and .25mm Pb in the back. When worn, the overlap areas in the front of both the skirt and vest provide 1.0mm Pb protection. The velcro fastene...
Designed to fit the body and priced to fit the budget! The Economy Tie apron has a belt that wraps around the body and ties in the front. Don't let the price fool you.... this apron provides the same...
Setting a new standard in protective apparel. The unique, patented Cool-Tech™ mesh-back design fits the natural contour of the body while reducing the amount of weight carried on the shoulders ...
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Medicine Products: